START study
Phase 1
- Conditions
- HIV InfectionTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2008-006439-12-EE
- Lead Sponsor
- Regents of the University of Minnesota
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 4600
Inclusion Criteria
All HIV-positive participants in START are eligible to continue in extended follow-up
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 4590
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of early antiretroviral therapy in HIV infection as studied in START?
How does the START trial compare to standard-of-care treatment strategies for HIV in terms of virologic and immunologic outcomes?
What biomarkers are associated with treatment response or non-response in the START phase I HIV intervention trial?
What are the potential adverse events and management strategies for early ART initiation as evaluated in START?
What combination therapies or competitor drugs are being explored alongside early ART in HIV clinical research post-START?